nach oben

General Thoracic and Cardiovascular Surgery

Erschienen in:

01.07.2014 | Current Topics Review Article

Lymph node dissection for lung cancer: past, present, and future

verfasst von: Shun-ichi Watanabe

Erschienen in: General Thoracic and Cardiovascular Surgery | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

In 1978, Naruke et al. proposed an anatomical map that included numbered lymph node stations, which then became widely used for nodal dissection. In 1997, Mountain and Dresler published a new map, which is now favored by the American Thoracic Society and the European Respiratory Society. Using these maps, regional nodal dissection has been universally performed in lung cancer surgery. Clear evidence regarding the survival benefit of lymph node dissection for lung cancer is lacking. However, lobectomy with lymph node dissection continues to be a standard surgical procedure for lung cancer because lymph node dissection is an important investigative process in staging patients. Over the last decade, the extent of nodal dissection for lung cancer has changed due to the increasing number of early detected lung cancers made possible by the recent development of the CT scanner. This manuscript describes the history, present strategy, and future perspectives of lymph node dissection for lung cancer.

Cahan WG. Radical lobectomy. J Thorac Cardiovasc Surg. 1960;39:555–72.PubMed

Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thoracic Cardiovasc Surg. 1978;76:832–9.

Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718–23.PubMedCrossRef

American Thoracic Society. Clinical staging of primary lung cancer. Am Rev Respir Dis. 1983;127:659–64.

American Thoracic Society. European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med. 1997;156:320–2.CrossRef

Cahan WG, Watson WL, Pool JL. Radical pneumonectomy. J Thorac Surg. 1951;22:449–73.PubMed

Nohl HC. An investigation into the lymphatic and vascular spread of carcinoma of the bronchus. Thorax. 1956;11:172–85.PubMedCentralPubMedCrossRef

The Japan Lung Cancer Society. Classification of lung cancer. First English edition. Tokyo: Kanehara & Co. Ltd.; 2000.

Goldstraw P. Report on the international workshop on intrathoracic staging, London, October 1996. Lung Cancer. 1997;18:107–11.CrossRef

10.

The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;22:3860–7.

11.

Winton TL, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–97.PubMedCrossRef

12.

Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg. 2006;30:787–92.PubMedCrossRef

13.

Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol. 2003;21:1029–34.PubMedCrossRef

14.

Doddoli C, Aragon A, Barlesi F, Chetaille B, Robitail S, Giudicelli R, et al. Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur J Cardiothorac Surg. 2005;27:680–5.PubMedCrossRef

15.

Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M. Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg. 2006;30:164–7.PubMedCrossRef

16.

Keller SM, Adak S, Wagner H, Johnson DH. Mediastinal lymph node dissection improves survival in patients with stage II and IIIa non-small cell lung cancer. Ann Thorac Surg. 2000;70:358–66.PubMedCrossRef

17.

Dales RE, Stark RM, Raman S. Computed tomography to stage lung cancers: approaching a controversy using meta-analysis. Am Rev Respir Dis. 1990;141:1096–101.PubMedCrossRef

18.

Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s––meta-analytic comparison of PET and CT. Radiology. 1999;213:530–6.PubMedCrossRef

19.

Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer. A meta-analysis. Ann Int Med. 2003;139:879–900.PubMedCrossRef

20.

Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko-PET der Deutschen Gesellschaft fur Nuklearmedizin. Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000. Pneumologie. 2001;55:367–77.PubMedCrossRef

21.

Oda M, Watanabe Y, Shimizu J, Murakami S, Ohta Y, Sekido N, et al. Extent of mediastinal node metastasis in clinical stage I non-small-cell lung cancer: the role of systematic nodal dissection. Lung Cancer. 1998;22:23–30.PubMedCrossRef

22.

Mountain CF. A new international staging system for lung cancer. Chest. 1986;89:225S–33S.PubMedCrossRef

23.

Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.PubMedCrossRef

24.

Watanabe S, Asamura H, Suzuki K, Tsuchiya R. Problems in diagnosis and surgical management of clinical N1 non-small cell lung cancer. Ann Thorac Surg. 2005;79:1682–5.PubMedCrossRef

25.

Graham AN, Chan KJ, Pastorino U, Goldstraw P. Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. J Thoracic Cardiovasc Surg. 1999;117:246–51.CrossRef

26.

Watanabe S, Oda M, Go T, Tsunezuka Y, Ohta Y, Watanabe Y, et al. Should mediastinal nodal dissection be routinely undertaken in patients with peripheral small-sized lung cancer? Retrospective analysis of 225 patients. Eur J Cardiothorac Surg. 2001;20:1007–11.PubMedCrossRef

27.

Takizawa T, Terashima M, Koike T, Akamatsu H, Kurita Y, Yokoyama A. Mediastinal lymph node metastasis in patients with clinical stage I peripheral non-small-cell lung cancer. J Thorac Cardiovasc Surg. 1997;113:248–52.PubMedCrossRef

28.

Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer. Eur J Cardiothorac Surg. 2004;25:502–8.PubMedCrossRef

29.

Gunluoglu Z, Solak O, Metin M, Gurses A. The prognostic significance of skip mediastinal lymphatic metastasis in resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2002;21:595.PubMedCrossRef

30.

Riquet M, Hidden G, Debesse B. Direct lymphatic drainage of lung segments to the mediastinal nodes. An anatomic study on 260 adults. J Thorac Cardiovasc Surg. 1989;97:623–32.PubMed

31.

Yoshino I, Yokoyama H, Yano T, Ueda T, Takai E, Mizutani K, et al. Skip metastasis to the mediastinal lymph nodes in non-small cell lung cancer. Ann Thoracic Surg. 1996;62:1021–5.CrossRef

32.

Prenzel KL, Monig SP, Sinning JM, Baldus SE, Gutschow CA, Grass G, et al. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancers. J Surg Oncol. 2003;82:256–60.PubMedCrossRef

33.

Pignon JP, Tribodet H, Scagliotti G, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol. 2008;26:3552–9.PubMedCrossRef

34.

Darling GE, Allen MS, Decker PA, et al. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141:662–70.PubMedCrossRef

35.

Bollen EC, van Duin CJ, Theunissen PH, vt Hof-Grootenboer BE, Blijham GH. Mediastinal lymph node dissection in resected lung cancer: morbidity and accuracy of staging. Ann Thorac Surg. 1993;55:961–6.PubMedCrossRef

36.

Thomas PA, Piantadosi S, Mountain CF. The Lung Cancer Study Group. Should subcarinal lymph nodes be routinely examined in patients with non-small cell lung cancer? J Thorac Cardiovasc Surg. 1988;95:883–7.

37.

Izbicki JR, Passlick B, Karg O, Bloechle C, Pantel K, Knoefel WT, et al. Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg. 1995;59:209–14.PubMedCrossRef

38.

Watanabe S, Oda M, Tsunezuka Y, Go T, Ohta Y, Watanabe G. Peripheral small-sized (2 cm or less) non-small cell lung cancer with mediastinal lymph node metastasis; clinicopathologic features and patterns of nodal spread. Eur J Cardiothorac Surg. 2002;22:995–9.PubMedCrossRef

39.

Kawano R, Hata E, Ikeda S, Sakaguchi H. Micrometastasis to lymph nodes in stage I left lung cancer patients. Ann Thorac Surg. 2002;73:1558–62.PubMedCrossRef

40.

Lardinois D, Suter H, Hakki H, Rousson V, Betticher D, Ris HB. Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2005;80:268–74.PubMedCrossRef

41.

Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg. 1988;46:603–10.PubMedCrossRef

42.

Watanabe Y, Hayashi Y, Shimizu J, Oda M, Iwa T. Mediastinal nodal involvement and the prognosis of non-small cell lung cancer. Chest. 1991;100:422–8.PubMedCrossRef

43.

Nakahara K, Fujii Y, Matsumura A, Minami M, Okumura M, Matsuda H. Role of systematic mediastinal dissection in N2 non-small cell lung cancer patients. Ann Thorac Surg. 1993;56:331–5.PubMedCrossRef

44.

Pearson FG. Non-small cell lung cancer: role of surgery for stages I–III. Chest. 1999;116:500S–3S.PubMedCrossRef

45.

Keller SM, Vangel MG, Wagner H, Schiller JH, Herskovic A, Komaki R, et al. Eastern Cooperative Oncology Group. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg. 2004;128:130–7.PubMedCrossRef

46.

Izbicki JR, Passlick B, Pantel K, Pichlmeier U, Hosch SB, Karg O, et al. Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small lung cancer. Ann Surg. 1998;227:138–44.PubMedCentralPubMedCrossRef

47.

Sugi K, Nawata K, Fujita N, Ueda K, Tanaka T, Matsuoka T, et al. Systematic lymph node dissection for clinically diagnosed peripheral non-small-cell lung cancer less than 2 cm in diameter. World J Surg. 1998;22:290–5.PubMedCrossRef

48.

Wu Y, Huang ZF, Wang SY, Yang XN, Ou W. A randomized trial of systematic nodal dissection in resectable non-small cell lung cancer. Lung Cancer. 2002;36:1–6.PubMedCrossRef

49.

Wright G, Manser RL, Bymes G, Hart D, Campbell DA. Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. Thorax. 2006;61:597–603.PubMedCentralPubMedCrossRef

50.

Detterbeck F. What do with “surprise” N2? Intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol. 2008;3:289–302.PubMedCrossRef

51.

The CONSORT statement. Web site: http://www.consort-statement.org.

52.

Watanabe S, Ladas G, Goldstraw P. Inter-observer variability in systematic nodal dissection: comparison of European and Japanese nodal designation. Ann Thorac Surg. 2002;73:245–8.PubMedCrossRef

53.

Sobin LH, Gospodarowicz M, Wittekind CH, UICC International Union Against Cancer, editors. TNM classification of malignant tumours. 7th ed. New York: Wiley-Liss; 2009.

54.

Luzzi L, Paladini P, Ghiribelli C, Voltolini L, Di Bisceglie M, D’Agata A, et al. Assessing the prognostic value of the extent of mediastinal lymph node infiltration in surgically treated non-small cell lung cancer (NSCLC). Lung Cancer. 2000;30:99–105.PubMedCrossRef

55.

Asamura H, Nakayama H, Kondo H, Tsuchiya R, Naruke T. Lobe-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis. J Thorac Cardiovasc Surg. 1999;117:1102–11.PubMedCrossRef

56.

Okada M, Sakamoto T, Yuki T, Mimura T, Miyoshi K, Tsubota N. Selective mediastinal lymphadenectomy for clinico-surgical stage I non-small cell lung cancer. Ann Thorac Surg. 2006;81:1028–32.PubMedCrossRef

57.

Okada M, Tsubota N, Yoshimura M, Miyamoto Y. Proposal for reasonable mediastinal lymphadenectomy in bronchogenic carcinomas: role of subcarinal nodes in selective dissection. J Thorac Cardiovasc Surg. 1998;116:949–53.PubMedCrossRef

58.

Watanabe S, Asamura H, Suzuki K, Tsuchiya R. The new strategy of selective nodal dissection for lung cancer based on segment-specific patterns of nodal spread. Interact Cardiovasc Thorac Surg. 2005;4:106–9.PubMedCrossRef

59.

Cerfolio RJ, Bryant AS. Distribution and likelihood of lymph node metastasis based on the lobar location of nonsmall-cell lung cancer. Ann Thorac Surg. 2006;81:1969–73.PubMedCrossRef

60.

Naruke T, Tsuchiya R, Kondo H, Nakayama H, Asamura H. Lymph node sampling in lung cancer. How should it be done? Eur J Cardiothorac Surg. 1999;16(Suppl 1):17–24.CrossRef

61.

Rami-Porta R, Wittekind C, Goldstraw P. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005;49:25–33.PubMedCrossRef

62.

Ginsberg RJ. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas. J Thorac Cardiovasc Surg. 1996;111:1123–4.PubMedCrossRef

63.

Allen MS, Darling GE, Pechet TT, Mitchell JD, Herndon JE 2nd, Landreneau RJ, et al. Morbidity and mortality of major pulmonary resections in patients with early stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Ann Thorac Surg. 2006;81:1013–9.PubMedCrossRef

Titel: Lymph node dissection for lung cancer: past, present, and future
verfasst von: Shun-ichi Watanabe
Publikationsdatum: 01.07.2014
Verlag: Springer Japan
Erschienen in: General Thoracic and Cardiovascular Surgery / Ausgabe 7/2014
Print ISSN: 1863-6705
Elektronische ISSN: 1863-6713
DOI: https://doi.org/10.1007/s11748-014-0412-z

Neu im Fachgebiet Chirurgie

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Early outcomes and hemodynamics after implantation of the Trifecta aortic bioprosthesis

Histological assessment of transmurality after repeated radiofrequency ablation of the left atrial wall

Cardiac myxosarcoma with thoracic spinal metastasis

Rib tumors: a 15-year experience

How to prevent spinal cord injury during endovascular repair of thoracic aortic disease

Thoracoscopic resection of a giant mediastinal parathyroid cyst

Update Chirurgie